Jim Bush

930 total citations · 1 hit paper
24 papers, 638 citations indexed

About

Jim Bush is a scholar working on Dermatology, Immunology and Surgery. According to data from OpenAlex, Jim Bush has authored 24 papers receiving a total of 638 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Dermatology, 4 papers in Immunology and 3 papers in Surgery. Recurrent topics in Jim Bush's work include Dermatologic Treatments and Research (4 papers), Wound Healing and Treatments (3 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (2 papers). Jim Bush is often cited by papers focused on Dermatologic Treatments and Research (4 papers), Wound Healing and Treatments (3 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (2 papers). Jim Bush collaborates with scholars based in United Kingdom, United States and Japan. Jim Bush's co-authors include Wayne Holman, Laura J. Szewczyk, Firas Almazedi, George R. Painter, Wendy Painter, Merribeth J. Morin, Mark W. J. Ferguson, Sharon O’Kane, Nick L. Occleston and Tracey Mason and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and PLoS ONE.

In The Last Decade

Jim Bush

23 papers receiving 613 citations

Hit Papers

Human Safety, Tolerability, and Pharmacokinetics of Molnu... 2021 2026 2022 2024 2021 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2
    2021 274 citations Wendy Painter, Wayne Holman et al. Antimicrobial Agents and Chemotherapy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jim Bush United Kingdom 14 222 138 110 87 59 24 638
Fernanda Scopelliti Italy 14 132 0.6× 97 0.7× 72 0.7× 144 1.7× 53 0.9× 23 651
Yosuke Yamamoto Japan 15 53 0.2× 191 1.4× 27 0.2× 78 0.9× 11 0.2× 51 736
Lixiang Wang China 15 72 0.3× 142 1.0× 18 0.2× 76 0.9× 83 1.4× 58 624
Sandeep Goswami India 15 118 0.5× 245 1.8× 19 0.2× 38 0.4× 57 1.0× 34 528
Jing Bi China 18 96 0.4× 313 2.3× 12 0.1× 98 1.1× 104 1.8× 48 768
Shamila D. Alipoor Iran 14 159 0.7× 556 4.0× 16 0.1× 95 1.1× 275 4.7× 31 1.0k
Jianqiang Ding China 14 90 0.4× 227 1.6× 30 0.3× 100 1.1× 125 2.1× 22 693
Yujun Chen China 14 38 0.2× 196 1.4× 57 0.5× 78 0.9× 34 0.6× 67 706

Countries citing papers authored by Jim Bush

Since Specialization
Citations

This map shows the geographic impact of Jim Bush's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jim Bush with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jim Bush more than expected).

Fields of papers citing papers by Jim Bush

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jim Bush. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jim Bush. The network helps show where Jim Bush may publish in the future.

Co-authorship network of co-authors of Jim Bush

This figure shows the co-authorship network connecting the top 25 collaborators of Jim Bush. A scholar is included among the top collaborators of Jim Bush based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jim Bush. Jim Bush is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gayà, Anna, Talha Munir, Álvaro Urbano-Ispizúa, et al.. (2023). Results of a phase 1/2 study of cemdisiran in healthy subjects and patients with paroxysmal nocturnal hemoglobinuria. SHILAP Revista de lepidopterología. 4(3). 612–624. 13 indexed citations
2.
Cheung, Dorothy, Alice Fong, Han Ting Ding, et al.. (2021). A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects. Pulmonary Pharmacology & Therapeutics. 69. 102051–102051. 5 indexed citations
3.
Painter, Wendy, Wayne Holman, Jim Bush, et al.. (2021). Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2. Antimicrobial Agents and Chemotherapy. 65(5). 274 indexed citations breakdown →
4.
Tan, Tricia, James Minnion, Bernard Khoo, et al.. (2021). Weight Loss With a Novel Peptide YY Analogue for Obesity: A Randomised, Placebo-Controlled Phase I Trial. Journal of the Endocrine Society. 5(Supplement_1). A32–A32. 1 indexed citations
5.
6.
7.
Höchel, Joachim, Olaf Prien, Torsten Zimmermann, et al.. (2018). Characterization of the Pharmacokinetics of Vilaprisan: Bioavailability, Excretion, Biotransformation, and Drug–Drug Interaction Potential. Clinical Pharmacokinetics. 57(8). 1001–1015. 25 indexed citations
8.
9.
Wilbraham, Darren, et al.. (2016). Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel‐group, phase I study in healthy subjects. British Journal of Clinical Pharmacology. 83(5). 1011–1027. 33 indexed citations
10.
Najafian, Nader, Anita Hill, Jörg Täubel, et al.. (2016). SP200A SUBCUTANEOUSLY ADMINISTERED INVESTIGATIONAL RNAI THERAPEUTIC (ALN-CC5) TARGETING COMPLEMENT C5 FOR TREATMENT OF PNH AND COMPLEMENT-MEDIATED DISEASES:INTERIM PHASE 1 STUDY RESULTS. Nephrology Dialysis Transplantation. 31(suppl_1). i153–i153. 1 indexed citations
11.
Juif, Pierre‐Éric, Matthias Hoch, Andrea Vaclavkova, et al.. (2016). Mitigation of Initial Cardiodynamic Effects of the S1P1 Receptor Modulator Ponesimod Using a Novel Up‐Titration Regimen. The Journal of Clinical Pharmacology. 57(3). 401–410. 17 indexed citations
12.
13.
Wong, Jason, Anthony D. Metcalfe, Richard Wong, et al.. (2014). Reduction of Tendon Adhesions following Administration of Adaprev, a Hypertonic Solution of Mannose-6-Phosphate: Mechanism of Action Studies. PLoS ONE. 9(11). e112672–e112672. 15 indexed citations
14.
Occleston, Nick L., Sharon O’Kane, Hugh Laverty, et al.. (2011). Discovery and development of avotermin (recombinant human transforming growth factor beta 3): A new class of prophylactic therapeutic for the improvement of scarring. Wound Repair and Regeneration. 19(s1). s38–48. 68 indexed citations
15.
McCollum, P T, Jim Bush, Thomas Mason, et al.. (2011). Randomized phase II clinical trial of avotermin versus placebo for scar improvement. British journal of surgery. 98(7). 925–934. 39 indexed citations
16.
Jossinet, J., John Byrne, Julian Chantrey, et al.. (2010). Remote Wound Monitoring of Chronic Ulcers. IEEE Transactions on Information Technology in Biomedicine. 14(2). 371–377. 20 indexed citations
17.
Bush, Jim, Karen So, Tracey Mason, et al.. (2010). Therapies with Emerging Evidence of Efficacy: Avotermin for the Improvement of Scarring. Dermatology Research and Practice. 2010(1). 14 indexed citations
18.
Bush, Jim, et al.. (2001). Dietary fat supplementation effects on in vitro nutrient disappearance and in vivo nutrient intake and total tract digestibility by horses.. Journal of Animal Science. 79(1). 232–232. 25 indexed citations
19.
Bush, Jim, et al.. (1976). Some implementations of segment sequential functions. 178–185. 12 indexed citations
20.
Bush, Jim, et al.. (1960). Comparative clinical effects of hydrochlorothiazide and methyclothiazide.. PubMed. 2. 430–5. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fernanda Scopelliti Breakdown of academic impact, for papers by Yosuke Yamamoto Breakdown of academic impact, for papers by Lixiang Wang Breakdown of academic impact, for papers by Sandeep Goswami Breakdown of academic impact, for papers by Jing Bi Breakdown of academic impact, for papers by Shamila D. Alipoor Breakdown of academic impact, for papers by Jianqiang Ding Breakdown of academic impact, for papers by Yujun Chen
Rankless by CCL
2026